Oncogenic action of phospholipase A2 in prostate cancer

Cancer Letters

Volumn 240, Issue 1, 2006, Pages 9-16

  Dong, Qihan ^a,b   Patel, Manish ^a   Scott, Kieran F ^c   Graham, Garry G ^d   Russell, Pamela J ^e   Sved, Paul ^b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d ST VINCENT S HOSPITAL   (Australia)

^e PRINCE OF WALES HOSPITAL   (Australia)

Author keywords

Annexin A1; Annexin A2; Cyclooxygenase; Cytosolic phospholipase A2; Eicosanoids; Lipoxygenase; Secreted phospholipase A2

Indexed keywords

ANDROGEN; HORMONE DERIVATIVE; LIPOCORTIN 1; LIPOCORTIN 2; LIPOXYGENASE; LIPOXYGENASE INHIBITOR; METRIBOLONE; PHOSPHOLIPASE A2; PHOSPHOLIPASE A2 INHIBITOR; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR; PYRROLIDINE DERIVATIVE;

AMINO TERMINAL SEQUENCE; ANDROGEN ABLATION THERAPY; ANDROGEN THERAPY; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CELL CULTURE; CANCER GROWTH; CARBOXY TERMINAL SEQUENCE; CARCINOGENESIS; DOWN REGULATION; DRUG SAFETY; DRUG TARGETING; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ENZYME REGULATION; ENZYME RELEASE; EPIGENETICS; GENE MUTATION; GLEASON SCORE; HUMAN; IMMUNOAFFINITY CHROMATOGRAPHY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; INJECTION SITE REACTION; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEIN FUNCTION; SERIAL ANALYSIS OF GENE EXPRESSION; SHORT SURVEY; SOUTHERN BLOTTING; TUMOR XENOGRAFT; UPREGULATION;

ANIMALIA;

EID: 33745860033     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2005.08.012     Document Type: Review

References (61)

1. Gittes R.F. Carcinoma of the prostate. N. Engl. J. Med. 324 (1991) 236-245 [see comments]
2. Grayhack J.T., Keeler T.C., and Kozlowski J.M. Carcinoma of the prostate. Hormonal therapy. Cancer 60 (1987) 589-601
3. Millar D.S., Paul C.L., Molloy P.L., and Clark S.J. A distinct sequence (ATAAA)(n) separates methylated and unmethylated domains at the 5 '-end of the GSTP1 CpG island. J. Biol. Chem. 275 (2000) 24893-24899
4. Millar D.S., Ow K.K., Paul C.L., Russell P.J., Molloy P.L., and Clark S.J. Detailed methylation analysis of the glutathione S-transferase pi (GSTP1) gene in prostate cancer. Oncogene 18 (1999) 1313-1324
5. Cookson M.S., Reuter V.E., Linkov I., and Fair W.R. Glutathione s-transferase pi (gst-pi) class expression by immunohistochemistry in benign and malignant prostate tissue. J. Urol. 157 (1997) 673-676
6. Chetcuti A., Margan S.H., Russell P., Mann S., Millar D.S., Clark S.J., et al. Loss of annexin II heavy and light chains in prostate cancer and its precursors. Cancer Res. 61 (2001) 6331-6334
7. Paweletz C.P., Ornstein D.K., Roth M.J., Bichsel V.E., Gillespie J.W., Calvert V.S., et al. Loss of annexin 1 correlates with early onset of tumorigenesis in esophageal and prostate carcinoma. Cancer Res. 60 (2000) 6293-6297
8. Srivastava M., Bubendorf L., Srikantan V., Fossom L., Nolan L., Glasman M., et al. ANX7, a candidate tumor suppressor gene for prostate cancer. Proc. Natl. Acad. Sci. USA 98 (2001) 4575-4580
9. Raynal P., Pollard H.B., Annexins - the problem of assessing the biological role for a gene family of multifunctional calcium- and phospholipid-binding proteins [Review], Biochimica et Biophysica Acta - Reviews on Biomembranes 1197 (1994) 63-93.
10. Zimmer D.B., Cornwall E.H., Landar A., and Song W. The S100 protein family: history, function, and expression. Brain Res. Bull. 37 (1995) 417-429
11. Donato R. Perspectives in S-100 protein biology. Cell Calcium 12 (1991) 713-726
12. Kligman D., and Hilt D.C. The S100 protein family. Trends Biochem. Sci. 13 (1988) 437-443
13. Puisieux A., Ji J.W., and Ozturk M. Annexin II up-regulates cellular levels of P11 protein by a post-translational mechanism. Biochem. J. 313 (1996) 51-55
14. Rouault M., Bollinger J.G., Lazdunski M., Gelb M.H., Lambeau G., Novel mammalian group XII secreted phospholipase A2 lacking enzymatic activity, Biochemistry (Mosc) September 13 (2003) ASAP Article.
15. Scott K.F., Graham G.G., and Bryant K.J. Sectreted phospholipase A2 enzymes as therapeutic targets. Expert Opin. Ther. Targets 7 (2003) 427-440
16. Mizenina O., Musatkina E., Yanushevich Y., Rodina A., Krasilnikov M., de Gunzburg J., et al. A novel group IIA phospholipase A(2) interacts with v-Src oncoprotein from RSV-transformed hamster cells. J. Biol. Chem. 276 (2001) 34006-34012
17. Valentin E., and Lambeau G. Increasing molecular diversity of secreted phospholipases A(2) and their receptors and binding proteins. Biochim. Biophys. Acta 1488 (2000) 59-70
18. Six D.A., and Dennis E.A. The expanding superfamily of phospholipase A(2) enzymes: classification and characterization. Biochim. Biophys. Acta 1488 (2000) 1-19
19. Ohto T., Uozumi N., Hirabayashi T., and Shimizu T. Identification of novel cytosolic phospholipase A2s, murine cPLA2d, e, and t, which form a gene cluster with cPLA2b. J. Biol. Chem. 280 (2005) 24576-24583
20. Kim S., Ko J., Kim J.H., Choi E.C., and Na D.S. Differential effects of annexins I, II, III, and V on cytosolic phospholipase A2 activity: specific interaction model. FEBS Lett. 489 (2001) 243-248
21. Wu T., Angus C.W., Yao X.L., Logun C., and Shelhamer J.H. P11, a unique member of the S100 family of calcium-binding proteins, interacts with and inhibits the activity of the 85-kDa cytosolic phospholipase A2. J. Biol. Chem. 272 (1997) 17145-17153
22. Klee C.B. Ca2+-dependent phospholipid- (and membrane-) binding proteins. Biochemistry 27 (1988) 6645-6653
23. Yao X.L., Cowan M.J., Gladwin M.T., Lawrence M.M., Angus C.W., and Shelhamer J.H. Dexamethasone alters arachidonate release from human epithelial cells by induction of p11 protein synthesis and inhibition of phospholipase A2 activity. J. Biol. Chem. 274 (1999) 17202-17208
24. Davidson F.F., Dennis E.A., Powell M., and Glenney Jr. J.R. Inhibition of phospholipase A2 by "lipocortins" and calpactins. An effect of binding to substrate phospholipids. J. Biol. Chem. 262 (1987) 1698-1705
25. Haigler H.T., Schlaepfer D.D., and Burgess W.H. Characterization of lipocortin I and an immunologically unrelated 33-kDa protein as epidermal growth factor receptor/kinase substrates and phospholipase A2 inhibitors. J. Biol. Chem. 262 (1987) 6921-6930
26. Aarsman A.J., Mynbeek G., van den Bosch H., Rothhut B., Prieur B., Comera C., et al. Lipocortin inhibition of extracellular and intracellular phospholipases A2 is substrate concentration dependent. FEBS Lett. 219 (1987) 176-180
27. Ahn N.G., Teller D.C., Bienkowski M.J., McMullen B.A., Lipkin E.W., and de Haen C. Sedimentation equilibrium analysis of five lipocortin-related phospholipase A2 inhibitors from human placenta. Evidence against a mechanistically relevant association between enzyme and inhibitor. J. Biol. Chem. 263 (1988) 18657-18663
28. Breyer R.M., Kennedy C.R., Zhang Y., and Breyer M.D. Structure-function analyses of eicosanoid receptors. Physiologic and therapeutic implications. Ann. NY Acad. Sci. 905 (2000) 221-231
29. O'Flaherty J.T., Rogers L.C., Chadwell B.A., Owen J.S., Rao A., Cramer S.D., and Daniel L.W. 5(S)-Hydroxy-6,8,11,14-E,Z,Z,Z-eicosatetraenoate stimulates PC3 cell signaling and growth by a receptor-dependent mechanism. Cancer Res. 62 (2002) 6817-6819
30. Dennis E.A. The growing phospholipase A2 superfamily of signal transduction enzymes. Trends Biochem. Sci. 22 (1997) 1-2
31. Fukushima N., Ishii I., Contos J.J., Weiner J.A., Chun J., Lysophospholipid receptors.[erratum appears in Annu Rev Pharmacol Toxicol 2002;42:vii], Annual Review of Pharmacology & Toxicology. 41 (2001) 507-534.
32. Uozumi N., Kume K., Nagase T., Nakatani N., Ishii S., Tashiro F., et al. Role of cytosolic phospholipase A2 in allergic response and parturition. Nature 390 (1997) 618-622
33. Bonventre J.V., Huang Z., Taheri M.R., O'Leary E., Li E., Moskowitz M.A., and Sapirstein A. Reduced fertility and postischaemic brain injury in mice deficient in cytosolic phospholipase A2. Nature 390 (1997) 622-625
34. Sapirstein A., and Bonventre J.V. Specific physiological roles of cytosolic phospholipase A(2) as defined by gene knockouts. Biochim. Biophys. Acta 1488 (2000) 139-148
35. Uozumi N., and Shimizu T. Roles for cytosolic phospholipase A2alpha as revealed by gene-targeted mice. Prostaglandins Other Lipid Mediat. 68-69 (2002) 59-69
36. Chakraborti S. Phospholipase A(2) isoforms: a perspective. Cell. Signal. 15 (2003) 637-665
37. Hirabayashi T., Murayama T., and Shimizu T. Regulatory mechanism and physiological role of cytosolic phospholipase A2. Biol. Pharm. Bull. 27 (2004) 1168-1173
38. Mayer R.J., and Marshall L.A. New insights on mammalian phospholipase A2(s); comparison of arachidonoyl-selective and -nonselective enzymes. FASEB J. 7 (1993) 339-348
39. Mukherjee A.B., Miele L., and Pattabiraman N. Phospholipase A2 enzymes: regulation and physiological role. Biochem. Pharmacol. 48 (1994) 1-10
40. Satake Y., Diaz B.L., Balestrieri B., Lam B.K., Kanaoka Y., Grusby M.J., and Arm J.P. Role of group V phospholipase A2 in zymosan-induced eicosanoid generation and vascular permeability revealed by targeted gene disruption. J. Biol. Chem. 279 (2004) 16488-16494
41. Sawada H., Murakami M., Enomoto A., Shimbara S., and Kudo I. Regulation of type V phospholipase A2 expression and function by proinflammatory stimuli. Eur. J. Biochem. 263 (1999) 826-835
42. Enomoto A., Murakami M., Valentin E., Lambeau G., Gelb M.H., and Kudo I. Redundant and segregated functions of granule-associated heparin-binding group II subfamily of secretory phospholipases A2 in the regulation of degranulation and prostaglandin D2 synthesis in mast cells. J. Immunol. 165 (2000) 4007-4014
43. Murakami M., and Kudo I. Phospholipase A2. J. Biochem. 131 (2002) 285-292
44. Faas F.H., Dang A.Q., Pollard M., Hong X.M., Fan K., Luckert P.H., and Schutz M. Increased phospholipid fatty acid remodeling in human and rat prostatic adenocarcinoma tissues. J. Urol. 156 (1996) 243-248
45. Madaan S., Abel P.D., Chaudhary K.S., Hewitt R., Stott M.A., Stamp G.W., and Lalani E.N. Cytoplasmic induction and over-expression of cyclooxygenase-2 in human prostate cancer: implications for prevention and treatment. BJU Int. 86 (2000) 736-741
46. Zha S., Gage W.R., Sauvageot J., Saria E.A., Putzi M.J., and Ewing C.M. Cyclooxygenase-2 is up-regulated in proliferative inflammatory atrophy of the prostate, but not in prostate carcinoma. Cancer Res. 61 (2001) 8617-8623
47. Hsu A.L., Ching T.T., Wang D.S., Song X., Rangnekar V.M., and Chen C.S. The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. J. Biol. Chem. 275 (2000) 11397-11403
48. Gupta S., Srivastava M., Ahmad N., Sakamoto K., Bostwick D.G., and Mukhtar H. Lipoxygenase-5 is overexpressed in prostate adenocarcinoma. Cancer 91 (2001) 737-743
49. Ghosh J., and Myers C.E. Inhibition of arachidonate 5-lipoxygenase triggers massive apoptosis in human prostate cancer cells. Proc. Natl. Acad. Sci. USA 95 (1998) 13182-13187
50. Ablin R.J., and Shaw M.W. Prostaglandin modulation of prostate tumor growth and metastases. Anticancer Res. 6 (1986) 327-328
51. Rose D.P., and Connolly J.M. Effects of fatty acids and eicosanoid synthesis inhibitors on the growth of two human prostate cancer cell lines. Prostate 18 (1991) 243-254
52. Liu B., Maher R.J., Hannun Y.A., Porter A.T., and Honn K.V. 12(S)-HETE enhancement of prostate tumor cell invasion - selective role of PKC-alpha. J. Natl. Cancer. Inst. 86 (1994) 1145-1151
53. Leyton J., Manyak M.J., Mukherjee A.B., Miele L., Mantile G., and Patierno S.R. Recombinant human uteroglobin inhibits the in vitro invasiveness of human metastatic prostate tumor cells and the release of arachidonic acid stimulated by fibroblast-conditioned medium. Cancer Res. 54 (1994) 3696-3699
54. Patel M.I., Subbaramaiah K., Du B., Chang M., Yang P., Newman R.A., et al. Celecoxib inhibits prostate cancer growth: evidence of a cyclooxygenase-2-independent mechanism. Clin. Cancer Res. 11 (2005) 1999-2007
55. Nevalainen T.J., Haapamaki M.M., Gronroos J.M., Roles of secretory phospholipases A(2) in inflammatory diseases and trauma [Review], Biochimica et Biophysica Acta Molecular & Cell Biology of Lipids 1488 (2000) 83-90.
56. Huhtinen H.T., Gronroos J.M., Haapamaki M.M., Nevalainen T.J., Source of group II phospholipase A(2) in gastric juice. Roles of secretory phospholipases A(2) in inflammatory diseases and trauma [Review], Scandinavian Journal of Clinical & Laboratory Investigation 62 (2002) 123-128..
57. Kallajoki M., Alanen K.A., Nevalainen M., and Nevalainen T.J. Group II phospholipase A2 in human male reproductive organs and genital tumors. Prostate 35 (1998) 263-272
58. Graff J.R., Konicek B.W., Deddens J.A., Chedid M., Hurst B.M., and Colligan B. Expression of group IIa secretory phospholipase A2 increases with prostate tumor grade. Clin. Cancer Res. 7 (2001) 3857-3861
59. Jiang J.Z., Neubauer B.L., Graff J.R., Chedid M., Thomas J.E., and Roehm N.W. Expression of group IIA secretory phospholipase A2 is elevated in prostatic intraepithelial neoplasia and adenocarcinoma. Am. J. Pathol. 160 (2002) 667-671
60. Sved P., Scott K.F., McLeod D., King N., Singh J., Tsatralis T., et al. Oncogenic action of secreted phospholipase A2 in prostate cancer. Cancer Res. 64 (2004) 6934-6940
61. Sawada H., Murakami M., Enomoto A., Shimbara S., and Kudo I. Regulation of type V phospholipase A2 expression and function by proinflammatory stimuli. Eur. J. Biochem. 263 (1999) 826-835